Core Viewpoint - West Pharmaceutical Services (WST) is expected to report third-quarter 2025 results on October 23, with a history of earnings surprises, averaging 16.81% over the last four quarters [1] Q3 Estimates - The company anticipates third-quarter revenues between $785 million and $795 million, reflecting an organic sales growth of 2.5% to 3.5% [2] - Adjusted diluted earnings per share (EPS) are projected to be in the range of $1.65 to $1.70 [2] - The Zacks Consensus Estimate for revenues stands at $788 million, indicating a 5.5% increase year-over-year, while the consensus for earnings is $1.67 per share, showing a decline of 9.7% year-over-year [3] Revenue and Segment Performance - Total revenues are estimated at $786.8 million, representing a 3% organic improvement year-over-year, with adjusted EPS estimated at $1.66 [4] - Proprietary Products segment sales are expected to reach $638 million, reflecting an organic growth of 3.7%, while Contract-Manufactured Products segment sales are projected at $148.8 million [4] - Operating profit for Proprietary Products and Contract-Manufactured Products segments is likely to decline by 5.6% and 24.8%, respectively [4] Growth Drivers - The company is positioned for steady results, driven by the strength of its high-value product (HVP) portfolio, particularly in GLP-1 elastomer components and compliance upgrades in Europe [5] - The HVP delivery devices segment is expected to maintain solid demand, with ongoing evaluations of SmartDose for profitability improvements [6] - Contract manufacturing is anticipated to benefit from scaling production at the Dublin facility, partially offsetting weaknesses from certain product phase-outs [6] Challenges - Challenges include destocking effects in generics, capacity constraints in European facilities, and seasonal plant shutdowns, which may pressure gross margins [7][8] - Tariff-related headwinds of $15–$20 million for the year could also impact performance, depending on global trade developments [8]